Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Ovarian Cancer
Patient-Reported Outcomes Following Treatment with Niraparib
Read More
Ovarian Cancer
Safety and Efficacy of Lenvatinib + Pembrolizumab in Patients with Ovarian Cancer: LEAP-005
Read More
Ovarian Cancer
Phase 3 Trial of Tumor Treating Fields and Concomitant Weekly Paclitaxel for the Treatment of Platinum-Resistant Ovarian Cancer
Read More
Ovarian Cancer
Assessing Olaparib Combined with Pegylated Liposomal Doxorubicin for Treatment of Platinum-Resistant Ovarian Cancer
Read More
Ovarian Cancer
Efficacy of Niraparib in Potentially Difficult-to-Treat Patients with Newly Diagnosed Ovarian Cancer Based on BRCAwt Status
Read More
Ovarian Cancer
In Women with Platinum-Sensitive Ovarian Cancer, There Was No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib plus Cediranib
Read More
Ovarian Cancer
Impact of Visible Residual Disease, Other Risk Factors on Advanced Ovarian Cancer Progression and Death: Real-World Evidence
Read More
1
2
3
Page 3 of 3
Results 21 - 27 of 27